Open-Labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT).

Trial Profile

Open-Labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT).

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2011

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Metabolic syndrome
  • Focus Biomarker; Therapeutic Use
  • Acronyms EFFORT
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Apr 2010 Actual patient number (165) added as reported by ClinicalTrials.gov.
    • 03 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Dec 2009 Planned end date changed from 1 Nov 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top